Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.

On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 2036. Analysts cite new drugs and mechanisms, such as CD20, BAFF/APRILs, and next-generation complement inhibitors, as significant drivers of growth. The firm identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Amgen (AMGN), and Regeneron (REGN) as the key beneficiaries of this growth, while expressing a notable belief in an upside to current Wall Street estimates.

In a separate event, on March 18, 2026, Maxim upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Buy and maintained a $575 price target. According to the firm, Povetacicept has the potential to be a blockbuster with “pipeline-in-a-product” capabilities. The analyst further noted that, alongside Journavx and Casgevy, the company has three products that provide crucial diversification beyond its cystic fibrosis franchise.

Founded in 1989, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. Based in Massachusetts, the company develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.